BridgeMD
New treatment option for Hepatocellular Carcinoma
Official title Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
ClinicalTrials.gov ID: NCT05887661
What this study is testing
- What it's testing
- The goal of this clinical trial is to learn about goal-directed LCVP based on hypovolemic phlebotomy (HP) in laparoscopic hepatectomy. The main questions it aims to answer are: 1.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Clinical diagnosis of Hepatocellular Carcinoma
- Preference for laparoscopic hepatectomy and patient agreement
You likely can't join if
- Age \<18 years
- Pregnancy
- Refusal of blood product transfusion
- Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of...
- History of significant cerebrovascular disease
- Restrictive or obstructive pulmonary disease
See the full eligibility criteria
- Clinical diagnosis of Hepatocellular Carcinoma
- Preference for laparoscopic hepatectomy and patient agreement
- Age \<18 years
- Pregnancy
- Refusal of blood product transfusion
- Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure)
- History of significant cerebrovascular disease
- Restrictive or obstructive pulmonary disease
- Uncontrolled hypertension
- Renal dysfunction (glomerular filtration rate \<60 mL/min),
- Hemoglobin \<100 g/L
- Abnormal coagulation values (international normalized ratio \>1.5 not on warfarin and/or platelet count \<100 ×109/L)
- Evidence of hepatic metabolic disorder (bilirubin \>35 mmol/L)
- Presence of active infection
- Preoperative autologous blood donation
- Patients were not allowed to receive erythropoietin at any time during the index hospitalization.
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.